Gordon et al. [54] demonstrated increased inflammasome activation at the sites of dopaminergic cell loss in patients with end-stage PD by quantifying cleaved caspase-1 and inflammasome adaptor protein (ASC) in brain lysates of PD patients and controls by Western blotting. The gene discussed is CASP1; the disease is Parkinson disease.